On December 11, the life science sub forum of Dawan District Science Forum was held in Guangzhou. Zhong Nanshan, winner of the medal of the Republic, academician of the Chinese Academy of engineering and director of Guangzhou National Laboratory, delivered a speech at the sub forum of life sciences. He said, "China's vaccination should achieve theoretical mass immunization, and the vaccination rate should reach 83% of the whole population." At present, China's population that has completed the whole course of vaccination has reached 1.15 billion, accounting for 81.9% of the national population. He said that he is absolutely confident that the vaccination rate will reach 83% by the end of the year. A pressing matter of the moment, COVID-19 has four priorities: The first is the vaccine. He stressed that "only when it is fully injected into a certain proportion of the population can we achieve the mass immunization mentioned in historical experience". He introduced that the study found that the antibody of the vast majority of vaccines decreased half a year after injection, and booster injections were needed. At present, according to a large number of laboratory data, after two doses of vaccine, another dose of different types of booster, that is, allogeneic vaccination, will produce significantly increased antibodies, and the effect is very good. This needs further clinical demonstration. The second is antibody. A few days ago, the new crown monoclonal antibody neutralab monoclonal antibody / romicwell monoclonal antibody combined therapy developed by the third people's Hospital of Shenzhen and Tsinghua University and Tengsheng Bo medicine was approved to be listed. This is the first self-designed intellectual property COVID-19 neutralizing antibody combination therapy in China. It has been applied to critically ill patients in Yunnan, Qinghai and Inner Mongolia. Since the emergence of delta strain, the mortality of new crown patients in China is very low, and many Chinese therapies have played a great role. Third, we should develop drugs, especially small molecule drugs and traditional Chinese medicine. Zhong Nanshan introduced that this work has just started in the world, and everyone is promoting acceleration every day. At present, several small molecule drugs have been produced in China and are waiting for clinical verification. I believe they can catch up with the pace of the world soon. Another advantage of China is traditional Chinese medicine. Many research institutes are promoting research and are expected to enter clinical testing soon. Finally, Zhong Nanshan stressed that the emergence of Omicron has brought many new problems. At present, he does not understand the transmission law, pathogenesis and early case development, and knows little about medical treatment and drugs. Therefore, the interdisciplinary research in this field in various countries should work together. At present, it is necessary to strive for dynamic 0 transmission. The world needs to work together to overcome the epidemic with science and technology. He believes that the politicization of scientific and technological issues such as traceability and vaccines has greatly hindered and slowed down the global anti epidemic process. (Xinhua News Agency)